Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Breast Cancer × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 134 Parkinson Disease 4, Autosomal Dominant Lewy Body 118 Melanoma 94 Neoplasms 72 Squamous Cell Carcinoma of Head and Neck 60 Colorectal Neoplasms 42 Triple Negative Breast Neoplasms 38 Carcinoma, Renal Cell 37 Lung Neoplasms 35 Head and Neck Neoplasms 33 Breast Neoplasms 33 Stomach Neoplasms 32 Neoplasm Metastasis 32 Urinary Bladder Neoplasms 31 Carcinoma, Hepatocellular 31 Pancreatic Neoplasms 29 Ovarian Neoplasms 26 Carcinoma, Transitional Cell 25 Endometrial Neoplasms 19 Sarcoma 15 Recurrence 15 Esophageal Neoplasms 15 Uterine Cervical Neoplasms 14 Prostatic Neoplasms 14 Carcinoma, Squamous Cell 14 Small Cell Lung Carcinoma 13 Lymphoma 12 Cholangiocarcinoma 12 Carcinoma 12 Lymphoma, Non-Hodgkin 11

Interventions

Fulvestrant 5 Anastrozole 4 Letrozole 2 Docetaxel 2 Dasatinib 2 vandetanib 1 sonidegib 1 ribociclib 1 pembrolizumab 1 palbociclib 1 olaparib 1 irinotecan sucrosofate 1 exemestane 1 cediranib 1 XMT-1522 1 Vorinostat 1 Tablets 1 Population Groups 1 Paclitaxel 1 Moxifloxacin 1 Histone Deacetylase Inhibitors 1 Gemcitabine 1 FCN-437c 1 Everolimus 1 Electroporation 1 Cryosurgery 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡